Related Experiment Video
Updated: Jun 14, 2025
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
12.6K
Reducing therapeutic inertia in type 2 diabetes
Mark L Stroud1, Asif N Malik2, Shahid Ahmad3
1MBBS, MPH+TM, FRACGP, DipRACOG, Consultant Family Medicine, Mesaimeer Health Center, Primary Health Care Corporation, Qatar.
Australian Journal of General Practice
|September 3, 2024
Summary
Therapeutic inertia, a failure to intensify diabetes treatment, affects one-third of consultations. Addressing this system issue is key to improving patient outcomes and reducing cardiovascular risk in type 2 diabetes management.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Health Services Research
Background:
- Therapeutic inertia is defined as the failure to initiate or escalate treatment to achieve therapeutic goals.
- This phenomenon is observed in approximately one-third of type 2 diabetes management consultations.
- It represents a systemic issue in care delivery rather than individual physician or patient fault.
Purpose of the Study:
- To highlight the significance of reducing therapeutic inertia in type 2 diabetes.
- To emphasize the importance of comprehensive cardiovascular risk reduction strategies.
Main Methods:
- Discussion of various approaches to overcome treatment inertia.
- Introduction of the treat-to-target methodology.
- Explanation of the STABLE (Smoking cessation, Target organ involvement, HbA1c, Blood pressure, Lipid profile, Energy balance) acronym and practical implementation strategies.
Main Results:
- Evidence suggests therapeutic inertia is a significant barrier in diabetes care.
- Systematic approaches can be implemented to address and reduce this inertia.
- The treat-to-target methodology and STABLE framework offer practical guidance.
Conclusions:
- Reducing therapeutic inertia is crucial for optimizing type 2 diabetes management.
- Focusing on cardiovascular risk reduction alongside glycemic control is essential.
- Implementing structured approaches can improve treatment intensification and patient outcomes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
01:16Insulin: Dosing Regimen and Adverse Effects
160
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
160
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
01:36Carbohydrate Metabolism
10.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.9K
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306